Denali Therapeutics
DNLI | NASDAQ
$18.08
-$0.66 (-3.52%)
At close: Nov 16, 2026, 4:00 PM ET
$18.08
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Denali Therapeutics Company Profile
Company profile explainedCompany Profile
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Key Executives
| Name | Position |
|---|---|
| Ryan J. Watts | Co-Founder, President, Chief Executive Officer & Director |
| Alexander O. Schuth | Co-Founder, Chief Financial Officer, Chief Operating Officer & Secretary |
| Cindy Dunkle | Chief People Officer |
| Chris Walsh | General Counsel |
| Dana Andersen | Chief Technical and Manufacturing Officer |
| Joe Lewcock | Chief Scientific Officer |
| Katie Peng | Chief Commercial Officer |
| Peter Chin | Acting Chief Medical Officer & Head of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 09, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 04, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 28, 2026 | 8-K | Current Report |
| Jul 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Denali Therapeutics
| Country | United States |
| IPO Date | Dec 8, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 503 |
| CEO | Ryan J. Watts |
Contact Details
161 Oyster Point Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | DNLI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001714899 |
| CUSIP Number | 24823R105 |
| ISIN Number | US24823R1059 |
| SIC Code | 2836 |
Recent News
- 3 days ago / seekingalpha.comDenali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
- 3 days ago / seekingalpha.comDenali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
- 3 days ago / marketbeat.comDenali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
- 11 days ago / zacks.comDNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
- 13 days ago / seekingalpha.comDenali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comDenali Therapeutics Q3 Earnings Call Highlights
- 13 days ago / zacks.comDenali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
- 18 days ago / globenewswire.comDenali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
- 25 days ago / globenewswire.comDenali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
- 2 months ago / seekingalpha.comDenali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Add to Watchlist
Select watchlists to add or remove DNLI